Title: This Week in Pharma: Can Alder Beat Teva and Amgen In Treating Migraines? Will Positive Phase III Data Help Keryx’s Auryxia Receive Approval for an Expanded Indication?
Summary:
This column presents questions on CGRP migraine therapies and Keryx’s Auryxia. Based on your votes for the more interesting topic, Slingshot Insights will interview an expert and post a transcript.
Option 1: Evaluating the chances of approval and market potential for ALD403, TEV-48125, and AMG 334. Who can win approval and what role will these drugs play?
Option 2: Discussing growth prospects for Keryx’s Auryxia after a positive Phase III data readout. Will an expanded indication change the perception of the iron black box warning for physicians?
SLINGSHOT CONTRIBUTOR: Phil Loria
This column focuses on two companies that saw significant growth in their stock …show more content…
How do your patients respond to current treatment options?
How well validated and understood is the role that CGRP plays in Migraines?
What are the differences between current approved treatment options, and the CGRP therapies being developed by Alder, Teva, and Amgen?
What type of pricing could the migraine therapy market support or justify in your opinion?
Amgen and Alder are currently in Phase III testing, and Teva's TEV-48125 is in Phase II testing. Can you discuss the differences in the designs and standard measures of these trials?
Can you discuss the differences in the safety and efficacy profiles of ALD403, TEV-48125, and AMG334, and how each drug is administered? Do any of the drugs have an advantage over the others?
If approved, what type of patients would be most likely to use a CGRP antagonist therapy?
Given the current information, which drug do you think has the best chance to dominate the market assuming they all get approved? Which drug do you think you will give to your
Summary:
This column presents questions on CGRP migraine therapies and Keryx’s Auryxia. Based on your votes for the more interesting topic, Slingshot Insights will interview an expert and post a transcript.
Option 1: Evaluating the chances of approval and market potential for ALD403, TEV-48125, and AMG 334. Who can win approval and what role will these drugs play?
Option 2: Discussing growth prospects for Keryx’s Auryxia after a positive Phase III data readout. Will an expanded indication change the perception of the iron black box warning for physicians?
SLINGSHOT CONTRIBUTOR: Phil Loria
This column focuses on two companies that saw significant growth in their stock …show more content…
How do your patients respond to current treatment options?
How well validated and understood is the role that CGRP plays in Migraines?
What are the differences between current approved treatment options, and the CGRP therapies being developed by Alder, Teva, and Amgen?
What type of pricing could the migraine therapy market support or justify in your opinion?
Amgen and Alder are currently in Phase III testing, and Teva's TEV-48125 is in Phase II testing. Can you discuss the differences in the designs and standard measures of these trials?
Can you discuss the differences in the safety and efficacy profiles of ALD403, TEV-48125, and AMG334, and how each drug is administered? Do any of the drugs have an advantage over the others?
If approved, what type of patients would be most likely to use a CGRP antagonist therapy?
Given the current information, which drug do you think has the best chance to dominate the market assuming they all get approved? Which drug do you think you will give to your